Surprisingly, the reduced intratumoral CD8 T cell exhaustion upon anti-NKG2A treatment did not increase CD8 T cell activation nor ex vivo functionality, both in the tumor remission phase and later during tumor relapse. The gene discussed is KLRC1; the disease is neoplasm.